What is the recommended aspirin dose for a patient with peripheral arterial disease?

Aspirin Dosage for Peripheral Arterial Disease

For symptomatic PAD, use aspirin 75–160 mg once daily as monotherapy, or preferably combine aspirin 100 mg once daily with low-dose rivaroxaban 2.5 mg twice daily if the patient has high ischemic risk and non-high bleeding risk. 1

First-Line Antiplatelet Therapy for Symptomatic PAD

Single antiplatelet therapy (SAPT) with aspirin 75–160 mg once daily is a Class I, Level A recommendation for reducing major adverse cardiovascular events (MACE) in patients with symptomatic PAD. 1 This dose range is supported by the 2024 European Society of Cardiology guidelines as equivalent in efficacy to clopidogrel 75 mg daily. 1

• The specific aspirin dose of 100 mg once daily is recommended when combining with rivaroxaban 2.5 mg twice daily, which provides superior reduction in both MACE and major adverse limb events (MALE) compared to aspirin alone. 1, 2
• Research confirms that higher aspirin doses (325 mg) provide no additional benefit over 81 mg in PAD patients and do not reduce the composite outcome of death, myocardial infarction, or stroke. 3

Enhanced Dual Therapy for High-Risk PAD

Combination therapy with rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily should be considered (Class IIa, Level A) for patients with PAD who have: 1

• High ischemic risk (previous amputation, chronic limb-threatening ischemia, prior revascularization, heart failure, diabetes, or vascular disease in multiple beds) 1
• Non-high bleeding risk 1
• Post-revascularization status 1, 2

This combination is the only antithrombotic regimen that has demonstrated reduction in total mortality and cardiovascular mortality in PAD patients, making it the strongest evidence-based option for secondary prevention. 4

Post-Revascularization Antithrombotic Strategy

After lower-limb angioplasty, the preferred regimen is rivaroxaban 2.5 mg twice daily plus aspirin 81 mg daily (Class I, Level A), which reduces both cardiovascular events and limb-specific complications. 2

Alternative approach if rivaroxaban is contraindicated:

• Dual antiplatelet therapy (DAPT) with clopidogrel 75 mg plus aspirin 81 mg daily for 1–6 months (Class IIa, Level B) after endovascular revascularization 2
• Transition to single antiplatelet therapy after completing the DAPT course 2
• At least 1 month of DAPT may be considered to reduce limb events after revascularization 1

Alternative Single Antiplatelet Options

When dual therapy or rivaroxaban combinations are not feasible:

• Clopidogrel 75 mg once daily may be preferred over aspirin for reducing MI, stroke, and vascular death in symptomatic PAD 1
• Aspirin 75–160 mg once daily alone remains an acceptable alternative 1

Asymptomatic PAD Considerations

Routine antiplatelet therapy is NOT recommended for asymptomatic PAD without signs of clinically relevant atherosclerotic cardiovascular disease. 1

Exception: Aspirin 75–100 mg daily for primary prevention may be considered in asymptomatic PAD patients with diabetes mellitus, in the absence of contraindications. 1

Patients Requiring Anticoagulation for Other Indications

For patients on therapeutic anticoagulation (atrial fibrillation, mechanical valve):

• Use oral anticoagulant monotherapy alone (Class IIb recommendation) 1
• If adding antiplatelet therapy, use single agent aspirin 81 mg daily rather than dual antiplatelet therapy 2
• Avoid triple therapy (dual antiplatelet plus full-intensity anticoagulation) due to excessive bleeding risk 2

Contraindicated Approaches

Long-term DAPT in PAD patients is NOT recommended beyond the post-revascularization period. 1

Oral anticoagulant monotherapy for PAD (without another indication such as atrial fibrillation) is NOT recommended, as it fails to reduce MACE or MALE and increases bleeding. 1, 2

Ticagrelor is NOT routinely recommended for PAD patients. 1

Critical Dosing Distinction

The rivaroxaban dose for PAD (2.5 mg twice daily) is fundamentally different from the atrial fibrillation dose (20 mg once daily)—this low-dose regimen is essential for the cardiovascular and limb protection benefits while managing bleeding risk. 2

Bleeding Risk Considerations

Major bleeding risk is higher with rivaroxaban-aspirin compared to aspirin alone, but the reduction in cardiovascular and limb events outweighs this risk in appropriately selected patients without high bleeding risk. 1, 2